Last €1.99 EUR
Change Today -0.014 / -0.70%
Volume 320.3K
COX On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
As of 11:35 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

nicox sa (COX) Snapshot

Open
€2.01
Previous Close
€2.00
Day High
€2.04
Day Low
€1.96
52 Week High
01/16/14 - €2.93
52 Week Low
08/6/14 - €1.71
Market Cap
197.5M
Average Volume 10 Days
586.5K
EPS TTM
€-0.27
Shares Outstanding
99.2M
EX-Date
05/30/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NICOX SA (COX)

Related News

No related news articles were found.

nicox sa (COX) Related Businessweek News

View More BusinessWeek News

nicox sa (COX) Details

NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

171 Employees
Last Reported Date: 08/28/14
Founded in 1996

nicox sa (COX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €417.7K
Compensation as of Fiscal Year 2013.

nicox sa (COX) Key Developments

Nicox SA Announces Revenue Results for the Nine Months Ended September 30, 2014

Nicox SA announced revenue results for the nine months ended September 30, 2014. The company posted total revenues of EUR 4.5 million for the first nine months of 2014, compared with EUR 0.3 million for the same period in 2013. Total sales were EUR 4.0 million compared with EUR 0.3 million a year ago.

Nicox S.A. Launches Xailin Gel, Dry Eye Lubricant

Nicox S.A. announced the launch in Europe of Xailin Gel, a multidose carbomer gel lubricant (medical device) that becomes preservative-free in the eye. Once Xailin Gel is in contact with the eye surface, the substance released by the preservative is converted to water and oxygen by ocular enzymes, making Xailin Gel preservative-free in the eye. Xailin Gel follows Xailin Night and Xailin Fresh as the third medical device to be introduced in the Xailin(TM) range of dry eye lubricants. Xailin(TM) is a proprietary brand under which Nicox is commercializing a range of quality products for dry eye which are either preservative-free or preservative-free in the eye. Xailin Gel follows Xailin Night, a multi-dose preservative-free lubricating ointment for night-time relief of dry eye sensations, and Xailin Fresh, a unit-dose preservative-free lubricant that alleviates and soothes dry eye sensations, which were launched in early 2014. Other ocular lubricants are planned to be launched as part of the Xailin range by the end of 2014.

Nicox SA - Shareholder/Analyst Call

Nicox SA - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €1.99 EUR -0.014

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies
 

Industry Analysis

COX

Industry Average

Valuation COX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit www.nicox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.